-+ 0.00%
-+ 0.00%
-+ 0.00%

Telomir Pharmaceuticals Signs Linical Agreements for Breast Cancer Trial

PUBT·11/18/2026 13:07:02
Telomir Pharmaceuticals Signs Linical Agreements for Breast Cancer Trial
  • Telomir Pharmaceuticals signed a master services agreement and clinical trial work order with Linical to advance its Telomir-Zn study.
  • The FDA-cleared Phase 1/2 trial will evaluate the therapy in patients with advanced or metastatic triple-negative breast cancer.
  • Clinical initiation is targeted for the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-052994), on November 18, 2026, and is solely responsible for the information contained therein.